73858 Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity–Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis
Sohail Chaudhry(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Spyridon Gkalpakiotis(Charles University), Yi Liu(Nektar Therapeutics (United States)), Richard Warren(Manchester Academic Health Science Centre), Melinda Gooderham(Queen's University), Jonathan Silverberg(George Washington University), Thomas Bieber(DB Engineering & Consulting (Germany)), David Rosmarin(Indiana University School of Medicine), Raj Chovatiya(Rosalind Franklin University of Medicine and Science)
Cited by 0
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403
JAK inhibitors in the treatment of atopic dermatitis
|Journal of Allergy and Clinical Immunology|2021|361